Geovax Labsの空売り状況は、投資家がGeovax Labsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Geovax Labs (NASDAQ:GOVX) 株価情報, 空売り情報

Geovax Labs

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

Geovax Labs Inc

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy and maintains $8 price target.

News

Price Target

Reiteration

Analyst Ratings

GOVX

HC Wainwright & Co. Reiterates Buy on Geovax Labs, Maintains $8 Price Target

<h3>Gainers</h3>
<ul>
<li>Mural Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MURA#NASDAQ">MURA</a>) stock increased by 145.5% to $2.53 during Tuesday's regular session. The market value of their outstanding shares is at $43.5 million. </li>
<li>Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) stock moved upwards by 36.64% to $1.79. The market value of their outstanding shares is at $55.4 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) stock moved upwards by 32.57% to $3.98. The company's market cap stands at $7.6 million. </li>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) shares increased by 29.47% to $2.85. The market value of their outstanding shares is at $13.6 million. </li>
<li>Verve Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) shares increased by 24.51% to $5.13. The company's market cap stands at $455.5 million. </li>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) stock rose 21.12% to $0.99. The company's market cap stands at $7.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) stock declined by 55.9% to $0.14 during Tuesday's regular session. The market value of their outstanding shares is at $5.7 million. The company's, Q4 earnings came out today. </li>
<li>MetaVia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTVA#NASDAQ">MTVA</a>) stock declined by 37.78% to $1.15. The company's market cap stands at $9.9 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) shares decreased by 22.27% to $2.2. The market value of their outstanding shares is at $4.6 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares declined by 22.26% to $0.37. The market value of their outstanding shares is at $4.2 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) shares decreased by 21.73% to $0.84. The company's market cap stands at $7.9 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock fell 19.3% to $0.03. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

DWTX

MSPR

MTVA

MURA

PHIO

SKYE

SPRB

STSS

VERV

12 Health Care Stocks Moving In Tuesday's Intraday Session

U.S. stocks traded higher midway through trading, with the Dow Jones  index gaining around 50 points on Tuesday.
The Dow traded up 0.17% to 40,592.77 while the NASDAQ gained 0.39% to 16,896.58. The S&amp;P 500 also rose, gaining, 0.35% to 5,424.63.
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/04/44811469/how-to-earn-500-a-month-from-abbott-laboratories-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Abbott Laboratories Stock Ahead Of Q1 Earnings</a>
Leading and Lagging Sectors Financial shares surged by 1.2% on Tuesday.
In trading on Tuesday, health care shares fell by 0.3%.
Top Headline
Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) posted better-than-expected earnings for its first quarter.
Citigroup reported quarterly earnings of $1.96 per share which beat the analyst consensus estimate of $1.84 per share. The company reported quarterly sales of $21.60 billion which beat the analyst consensus estimate of $21.29 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Mural Oncology plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MURA#NASDAQ">MURA</a>) shares shot up 146% to $2.5299 after the company announced plans to explore strategic alternatives and discontinue clinical development of nemvaleukin.</li>
<li>Shares of Skye Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>)got a boost, surging 51% to $1.98 after the company reported weight loss results from its Nimacimab and Tirzepatide preclinical obesity model.</li>
<li>Rezolve AI PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) shares were also up, gaining 24% to $1.4160 as the company announced a $9.8 million yearly contract with Liverpool Mexico.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Spruce Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) shares dropped 59% to $0.1299 as the company announced new corporate strategy and acquisition of Tralesinidase Alfa for the treatment of Sanfilippo Syndrome Type B (MPS IIIB).</li>
<li>Shares of GeoVax Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) were down 31% to $0.7439 after multiple firms cut their respective price targets on the stock.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) was down, falling 27% to $3.9207 following weak quarterly revenue.</li>
</ul>
Commodities In commodity news, oil traded down 0.8% to $61.02 while gold traded up 0.4% at $3,237.90.
Silver traded up 0.1% to $32.180 on Tuesday, while copper fell 0.5% to $4.6015.
Euro zone
European shares were higher today. The eurozone's STOXX 600 jumped 1.69%, Germany's DAX 40 gained 1.51% and France's CAC 40 climbed 0.96%. Spain's IBEX 35 Index surged 2.09%, while London's FTSE 100 rose 1.45%.
Asia Pacific Markets
Asian markets closed higher on Tuesday, with Japan's Nikkei 225 gaining 0.84%, China's Shanghai Composite gaining 0.15%, Hong Kong's Gang Seng index rising 0.23% and India's BSE Sensex gaining 2.1%.
Economics
<ul>
<li>The NY Empire State Manufacturing Index climbed to -8.1 in April compared to -20 in the previous month.</li>
<li>U.S. export prices came in unchanged in March compared to a revised 0.5% gain in February.</li>
<li>U.S. import prices fell by 0.1% in March 2025 compared to a revised 0.2% gain in February.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/markets/25/04/44811698/jim-cramer-planet-fitness-is-doing-better-than-expected-says-no-to-this-industrial-stock">Jim Cramer: Planet Fitness Is Doing Better Than Expected, Says No To This Industrial Stock</a></li>
</ul>
Photo via Shutterstock

Earnings

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

APLD

RZLV

Crude Oil Moves Lower; Citigroup Posts Upbeat Results

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 100 points on Tuesday.
Following the market opening Tuesday, the Dow traded up 0.41% to 40,689.26 while the NASDAQ gained 0.60% to 16,932.04. The S&amp;P 500 also rose, gaining, 0.55% to 5,435.97.
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/04/44811469/how-to-earn-500-a-month-from-abbott-laboratories-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Abbott Laboratories Stock Ahead Of Q1 Earnings</a>
Leading and Lagging Sectors Financial shares surged by 1.3% on Tuesday.
In trading on Tuesday, health care shares fell by 0.3%.
Top Headline
Bank of America Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) posted better-than-expected earnings for its first quarter.
Bank of America reported quarterly earnings of 90 cents per share which beat the analyst consensus estimate of 81 cents per share. The company reported quarterly sales of $27.40 billion which beat the analyst consensus estimate of $26.99 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Mural Oncology plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MURA#NASDAQ">MURA</a>) shares shot up 139% to $2.46 after the company announced plans to explore strategic alternatives and discontinue clinical development of nemvaleukin.</li>
<li>Shares of Skye Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>)got a boost, surging 119% to $2.8699 after the company reported weight loss results from its Nimacimab and Tirzepatide preclinical obesity model.</li>
<li>Synergy CHC Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNYR#NASDAQ">SNYR</a>) shares were also up, gaining 71% to $3.0550.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Spruce Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) shares dropped 58% to $0.1327 as the company announced new corporate strategy and acquisition of Tralesinidase Alfa for the treatment of Sanfilippo Syndrome Type B (MPS IIIB).</li>
<li>Shares of GeoVax Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) were down 27% to $0.7768 after multiple firms cut their respective price targets on the stock.</li>
<li>Webull Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BULL#NASDAQ">BULL</a>) was down, falling 19% to $50.71.</li>
</ul>
Commodities In commodity news, oil traded up 0.2% to $61.64 while gold traded up 0.1% at $3,229.40.
Silver traded up 0.2% to $32.215 on Tuesday, while copper fell 0.5% to $4.6015.
Euro zone
European shares were higher today. The eurozone's STOXX 600 jumped 1.5%, Germany's DAX 40 gained 1.4% and France's CAC 40 climbed 0.7%. Spain's IBEX 35 Index surged 2%, while London's FTSE 100 rose 1.2%.
Asia Pacific Markets
Asian markets closed higher on Tuesday, with Japan's Nikkei 225 gaining 0.84%, China's Shanghai Composite gaining 0.15%, Hong Kong's Gang Seng index rising 0.23% and India's BSE Sensex gaining 2.1%.
Economics
<ul>
<li>The NY Empire State Manufacturing Index climbed to -8.1 in April compared to -20 in the previous month.</li>
<li>U.S. export prices came in unchanged in March compared to a revised 0.5% gain in February.</li>
<li>U.S. import prices fell by 0.1% in March 2025 compared to a revised 0.2% gain in February.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/44811698/jim-cramer-planet-fitness-is-doing-better-than-expected-says-no-to-this-industrial-stock">Jim Cramer: Planet Fitness Is Doing Better Than Expected, Says No To This Industrial Stock</a></li>
</ul>
Photo via Shutterstock

Equities

BULL

SNYR

Nasdaq Surges 100 Points; Bank of America Earnings Top Views

WIIM

GeoVax Labs shares are trading lower after multiple firms cut their respective price targets on the stock.

<h3>Gainers</h3>
<ul>
<li>Mural Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MURA#NASDAQ">MURA</a>) shares increased by 31.1% to $1.35 during Tuesday's pre-market session. The company's market cap stands at $23.2 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock rose 20.36% to $2.36. The company's market cap stands at $3.3 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares rose 17.36% to $0.58. The market value of their outstanding shares is at $16.2 million. </li>
<li>Fractyl Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) stock rose 15.61% to $1.15. The company's market cap stands at $55.3 million. </li>
<li>MetaVia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTVA#NASDAQ">MTVA</a>) shares increased by 14.13% to $2.1. The company's market cap stands at $18.1 million. </li>
<li>Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) shares increased by 12.73% to $5.03. The company's market cap stands at $52.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Elutia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELUT#NASDAQ">ELUT</a>) shares fell 54.7% to $0.91 during Tuesday's pre-market session. The market value of their outstanding shares is at $37.1 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) shares decreased by 29.92% to $0.75. The company's market cap stands at $7.0 million. </li>
<li>Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) stock fell 23.35% to $0.24. The company's market cap stands at $9.9 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) stock fell 21.34% to $1.4. The market value of their outstanding shares is at $18.6 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares decreased by 21.03% to $0.16. The market value of their outstanding shares is at $4.8 million. </li>
<li>Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) stock decreased by 20.42% to $2.3. The company's market cap stands at $152.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DTIL

ELUT

ENSC

GUTS

ONMD

SOPH

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

D. Boral Capital analyst Jason Kolbert maintains Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy and lowers the price target from $18 to $14.

D. Boral Capital Maintains Buy on Geovax Labs, Lowers Price Target to $14

U.S. stock futures were volatile on Tuesday following a two-day advance. Futures of major benchmark indices were mixed in premarket.
Donald Trump hinted at helping the car companies while talking to reporters in his Oval Office on Monday. He explained that automakers require a transition period to shift production from Canada, Mexico, and elsewhere.
&#8220;And they need a little bit of time because they're going to make them here, but they need a little bit of time. So I'm talking about things like that,&#8221; he said.
Stocks advanced for two consecutive days after he exempted smartphones, computers, and semiconductors from the reciprocal tariffs on Friday. However, he hinted that he may look at levying duties on the chips imported into the U.S. on Sunday in a Truth Social post.
The 10-year Treasury bond yielded 4.38% and the two-year bond was at 3.86%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing an 82.7% likelihood of the Federal Reserve keeping the current interest rates unchanged in its May meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.03%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.08%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.25%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.12%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Tuesday. The SPY was up 0.013% to $539.19, while the QQQ advanced 0.22% to $458.47, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Led by technology stocks, U.S. equities closed higher on Monday. Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares surged 2.2%, and Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELLL#NYSE">DELLL</a>) gained approximately 4%, contributing to a roughly 1% rise in the Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>).
Financials presented a mixed picture, with Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) reporting stronger-than-anticipated first-quarter earnings, while M&amp;T Bank Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) posted weaker-than-expected results.
Real estate, utilities, and consumer staples sectors recorded the most significant gains on Monday. Conversely, consumer discretionary stocks trended lower.
As of Monday&#8217;s close, the Dow Jones index was 10.1% lower than its 52-week high of 45,073.63 points. The S&amp;P 500 index was 12.06% lower than its previous high of 6,147.43 points, and the Nasdaq 100 index was down 15.42% from its last record high of 22,222.61 points.
The Dow Jones index climbed 312 points or 0.78% to 40,524.79, whereas the S&amp;P 500 index advanced 0.79% to 5,405.97. Nasdaq Composite rose to end 0.64% higher at 16,831.48, and the small-cap gauge, Russell 2000, jumped 1.11% to 1,880.88.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.64%</td>
<td>16,831.48</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.79%</td>
<td>5,405.97</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.78%</td>
<td>40,524.79</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.11%</td>
<td>1,880.88</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Ark Invest CEO Cathie Wood said that she sees a &#8220;light at the end of the tunnel,&#8221; despite the ongoing<a href="https://www.benzinga.com/government/regulations/25/04/44807265/cathie-wood-says-shock-therapy-from-trumps-trade-moves-may-end-prolonged-economic-slump"> tariff turmoil</a>. According to Wood, tariffs could be the catalyst to end a three-year "rolling recession."
She said that Trump&#8217;s decision to bring Treasury Secretary Scott Bessent into the process indicates a move to reduce both tariffs and non-tariff trade obstacles. She contends this shift wouldn&#8217;t have occurred without the initial &#8220;shock therapy&#8221; of aggressive trade measures.
The slowdown caused by the tariff introduction will give the administration and the Federal Reserve "more degrees of freedom to stimulate than most investors have been expecting,&#8221; she said.
This will create a "clarion call" for tax cuts, deregulation, and lower interest rates, ultimately paving the way for economic recovery, Wood added.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">While the last two weeks of tariff turmoil have been challenging for financial markets, we see light at the end of the tunnel! <a href="https://t.co/cexMNdtbLp">https://t.co/cexMNdtbLp</a>
&mdash; Cathie Wood (@CathieDWood) <a href="https://twitter.com/CathieDWood/status/1911969728337186973?ref_src=twsrc%5Etfw">April 15, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The analysts at BlackRock extended their tactical horizon back to six to 12 months and resumed their positive view on U.S., while still expecting the &#8220;ongoing risk asset volatility and potentially sharp reversals.&#8221;
Spiking yields in long-term U.S. Treasuries seemed to be a factor in the change in tariff tactics, the weekly note stated.
&#8220;We stay underweight long-term Treasuries, our highest conviction view: tariffs are likely to add to already sticky inflation, and congressional budget plans last week reinforce the outlook for persistent budget deficits. We favor gold instead as a portfolio diversifier.&#8221;
According to BlackRock, the broad-based equity selloff has created opportunities to tap into certain sectors, and &#8220;selectivity is key.&#8221;
&#8220;We still like U.S. technology benefitting from the AI buildout and adoption. We also favor global banks. That includes U.S. banks given the scope for deregulation even with some potential economic pain.&#8221;
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Tuesday:
<ul>
<li>March&#8217;s import price index data and April&#8217;s Empire State manufacturing survey data will be released by 8:30 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) rose 1.09% in premarket on Tuesday as it is expected to report earnings before the opening bell. Analysts expect a quarterly earnings of $1.85 per share on revenue of $21.29 billion.</li>
</ul>
<ul>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) was down 0.29% as Wall Street expects it to report earnings of $2.60 per share on revenue of $21.58 billion before the opening bell.</li>
</ul>
<ul>
<li>Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) was up 0.76% as it is expected to report earnings before the opening bell. Analysts expect a quarterly earnings of 82 cents per share on revenue of $26.99 billion.</li>
</ul>
<ul>
<li>United Airlines Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) declined 0.12% as Wall Street expects it to report earnings of 76 cents per share on revenue of $13.26 billion after the closing bell.</li>
</ul>
<ul>
<li>Telefonaktiebolaget LM Ericsson ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) jumped 6.17% after reporting that its first-quarter adjusted operating earnings, excluding restructuring charges, jumped 44% year-over-year to 6.2 billion Swedish crowns ($636 million).</li>
</ul>
<ul>
<li>Lowe&#8217;s Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) advanced by 0.58% as it announced the purchase of an interior design company, Artisan Design Group, for $1.3 billion.</li>
</ul>
<ul>
<li>ARB IOT Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBB#NASDAQ">ARBB</a>) surged 33.83% after securing a $53 million deal to provide AI servers to Whizzl Group, boosting its AI infrastructure presence and strengthening its position in the AI and data center markets.</li>
</ul>
<ul>
<li>Geovax Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) slumped 34.57% after it was directed by the Biomedical Advanced Research and Development Authority on April 11 to halt its Phase 2b COVID-19 vaccine trial.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 0.29% to hover around $61.35 per barrel.
Gold Spot US Dollar advanced 0.46% to hover around $3,223.97 per ounce. Its fresh record high stood at $3,245.84 per ounce. The U.S. Dollar Index spot was lower by 0.06% at the 99.585 level.
Asian markets rose on Tuesday, including India's S&amp;P BSE Sensex, China&#8217;s CSI 300, Hong Kong's Hang Seng, Japan's Nikkei 225, Australia's ASX 200, and South Korea's Kospi index. European markets were also higher in early trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44807265/cathie-wood-says-shock-therapy-from-trumps-trade-moves-may-end-prolonged-economic-slump">Cathie Wood Says &#8216;Shock Therapy&#8217; From Trump&#8217;s Trade Moves May End Prolonged Economic Slump</a></li>
</ul>
Image Via Shutterstock

Analyst Color

Government

Economics

Federal Reserve

General

AAPL

ARBB

DELLL

ERIC

US Stock Futures Waver After Two-Day Rally: Trump's Tariff Moves Could End A 3-Year 'Rolling Recession,' Says Expert

Shares of Telefonaktiebolaget LM Ericsson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) rose sharply in today's pre-market trading following <a href="https://www.benzinga.com/quote/ERIC/earnings">first-quarter results.</a>
Ericsson reported that its first-quarter adjusted operating earnings, excluding restructuring charges, jumped 44% year-over-year to 6.2 billion Swedish crowns ($636 million). Its net sales rose 3% year-over-year to 55 billion crowns during the quarter.
Ericsson shares jumped 6.9% to $7.96 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Splash Beverage Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBEV#NYSE">SBEV</a>) rose 99.2% to $2.75 in pre-market trading after declining around 4% on Monday.</li>
<li>Synergy CHC Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNYR#NASDAQ">SNYR</a>) surged 55.3% to $2.78 in pre-market trading.</li>
<li>ARB IOT Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBB#NASDAQ">ARBB</a>) gained 42.5% to $0.9120 in pre-market after the company secured approximately $53.0 million order for supplying AI servers.</li>
<li>SUNation Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNE#NASDAQ">SUNE</a>) rose 17.8% to $0.0338 in pre-market trading after jumping around 28% on Monday.</li>
<li>CISO Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CISO#NASDAQ">CISO</a>) jumped 17.2% to $0.4699 in pre-market trading after jumping 19% on Monday.</li>
<li>USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) surged 16.6% to $13.70 in pre-market trading after gaining 41% on Monday.</li>
<li>Lionsgate Studios Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LION#NASDAQ">LION</a>) rose 14% to $7.10 in pre-market trading.</li>
<li>LXP Industrial Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LXP#NYSE">LXP</a>) gained 10.7% to $8.50 in pre-market trading.</li>
<li>Gamehaus Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMHS#NASDAQ">GMHS</a>) gained 9.5% to $1.46 in pre-market trading after gaining 23% on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>DiaMedica Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMAC#NASDAQ">DMAC</a>) fell 52% to $1.70 in pre-market trading.</li>
<li>Unifi, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UFI#NYSE">UFI</a>) shares tumbled 37.6% to $3.01 in pre-market trading after gaining around 4% on Monday.</li>
<li>GeoVax Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) fell 34.6% to $1.55 in pre-market trading after the company announced it received a notification from Advanced Technology International to stop all work on its efforts with respect to Project Agreement No. 01; RRPV-24-04-NGVx-006; &#8220;NextGen Vaccinations: Phase 2B Clinical Trial Execution: Phase 2b study to evaluate GEO-CM04S1 COVID-19 vaccine&#8221;</li>
<li>United Security Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBFO#NASDAQ">UBFO</a>) shares fell 34.1% to $5.00 in pre-market trading.</li>
<li>NAYA Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAYA#NASDAQ">NAYA</a>) shares fell 24.7% to $1.70 in pre-market trading. NAYA Biosciences is rebranding as INVO Fertility, and separating fertility and oncology divisions into distinct public and private entities.</li>
<li>Emerald Holding, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EEX#NYSE">EEX</a>) fell 12.3% to $3.11 in today's pre-market trading.</li>
<li>Allegro MicroSystems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) fell 12.3% to $19.29 in pre-market trading after ON Semiconductor withdrew its acquisition proposal.</li>
<li>Arlo Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARLO#NYSE">ARLO</a>) shares dipped 11.7% to $8.01 in pre-market trading. Arlo Technologies will hold a conference call on Thursday, May 8 to discuss the Company&#8217;s first quarter results.</li>
<li>IRSA Inversiones y Representaciones Sociedad Anónima (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRS#NYSE">IRS</a>) dipped 11.2% to $12.32 in pre-market trading after gaining around 9% on Monday.</li>
<li>Applied Digital Corporation  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) declined 10.8% to $4.79 in pre-market trading following weak quarterly revenue.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44787747/wall-streets-most-accurate-analysts-spotlight-on-3-consumer-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Consumer Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

ALGM

ARLO

CISO

DMAC

GMHS

LION

NAYA

SBEV

SUNE

UBFO

USAR

Why Ericsson Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Precision Optics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POCI#NASDAQ">POCI</a>) stock rose 21.4% to $4.7 during Monday's after-market session. The company's market cap stands at $35.8 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock increased by 15.01% to $0.25. The market value of their outstanding shares is at $11.0 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares rose 9.52% to $0.69. The company's market cap stands at $16.4 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares moved upwards by 8.26% to $4.06. The market value of their outstanding shares is at $2.6 million. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) shares moved upwards by 7.83% to $0.34. The company's market cap stands at $19.8 million. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) stock increased by 7.61% to $8.34. The market value of their outstanding shares is at $6.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) shares decreased by 29.9% to $0.75 during Monday's after-market session. The market value of their outstanding shares is at $7.0 million. </li>
<li>Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) stock fell 16.07% to $141.77. The company's market cap stands at $4.0 billion. </li>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock declined by 13.67% to $0.56. The company's market cap stands at $98.4 million. </li>
<li>Minerva Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) stock declined by 12.11% to $1.38. The market value of their outstanding shares is at $9.6 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock decreased by 10.42% to $0.21. The company's market cap stands at $1.3 million. </li>
<li>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) stock decreased by 9.31% to $1.17. The market value of their outstanding shares is at $12.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCAB

BSGM

CRIS

HCTI

KRYS

MCRB

NAOV

NERV

POCI

VERO

YCBD

12 Health Care Stocks Moving In Monday's After-Market Session

GeoVax Labs shares are trading lower after the company announced it received a notification from Advanced Technology International to stop all work on its efforts with respect to Project Agreement No. 01; RRPV-24-04-NGVx-006; "NextGen Vaccinations: Phase 2B Clinical Trial Execution: Phase 2b study to evaluate GEO-CM04S1 COVID-19 vaccine"

Biotech

GeoVax Directed By Advanced Technology International To Halt Work On Their Phase 2b Clinical Trial For The GEO-CM04S1 COVID-19 Vaccine, As Part Of A Project Funded By U.S. Department Of Health's BARDA Program.

D. Boral Capital analyst Jason Kolbert maintains Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy and maintains $18 price target.

D. Boral Capital Maintains Buy on Geovax Labs, Maintains $18 Price Target

<h3>Companies Reporting Before The Bell</h3>
• Tsakos Energy Navigation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEN#NYSE">TEN</a>) is projected to report quarterly earnings at $0.40 per share on revenue of $154.43 million. 
• Worksport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) is projected to report quarterly loss at $1.40 per share on revenue of $2.90 million. 
• PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) is projected to report earnings for its fourth quarter. 
• FitLife Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTLF#NASDAQ">FTLF</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $14.95 million. 
• ADC Therapeutics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>) is expected to report quarterly loss at $0.35 per share on revenue of $19.67 million. 
• Telesat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSAT#NASDAQ">TSAT</a>) is expected to report earnings for its fourth quarter. 
• Acumen Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABOS#NASDAQ">ABOS</a>) is expected to report earnings for its fourth quarter. 
• Bitfarms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BITF#NASDAQ">BITF</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $53.82 million. 
• Winnebago Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $608.95 million. 
• BK Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BKTI#AMEX">BKTI</a>) is estimated to report quarterly earnings at $0.35 per share on revenue of $16.80 million. 
• Edap TMS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $20.83 million. 
• TriSalus Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>) is likely to report quarterly loss at $0.35 per share on revenue of $8.24 million. 
• BIO-key Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) is likely to report quarterly loss at $0.35 per share on revenue of $2.29 million. 
• Icecure Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) is expected to report quarterly loss at $0.07 per share on revenue of $1.07 million. 
• Jiayin Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) is likely to report earnings for its fourth quarter. 
• Ascentage Pharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPG#NASDAQ">AAPG</a>) is projected to report earnings for its fourth quarter. 
• Urban One (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UONEK#NASDAQ">UONEK</a>) is estimated to report earnings for its fourth quarter. 
• Urban One (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UONE#NASDAQ">UONE</a>) is projected to report earnings for its fourth quarter. 
• TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) is likely to report quarterly earnings at $2.91 per share on revenue of $14.79 billion. 
• Sachem Cap (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SACH#AMEX">SACH</a>) is projected to report quarterly loss at $0.46 per share on revenue of $14.49 million. 
• Ermenegildo Zegna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZGN#NYSE">ZGN</a>) is likely to report earnings for its Fiscal Year 2024. 
• Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) is projected to report earnings for its Fiscal Year 2024. 
<h3>Companies Reporting After The Bell</h3>
• Dolphin Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $13.52 million. 
• Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) is projected to report earnings for its fourth quarter. 
• Draganfly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) is projected to report quarterly loss at $0.66 per share on revenue of $1.45 million. 
• Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) is projected to report quarterly loss at $0.09 per share on revenue of $3.85 million. 
• SeaStar Medical Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) is likely to report earnings for its fourth quarter. 
• INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) is projected to report earnings for its fourth quarter. 
• TMC Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) is estimated to report earnings for its fourth quarter. 
• Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) is expected to report quarterly loss at $0.40 per share on revenue of $9.03 million. 
• IZEA Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IZEA#NASDAQ">IZEA</a>) is expected to report quarterly loss at $0.08 per share on revenue of $13.00 million. 
• Yxt.Com Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YXT#NASDAQ">YXT</a>) is expected to report earnings for its fourth quarter. 
• TSS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSSI#NASDAQ">TSSI</a>) is expected to report earnings for its fourth quarter. 
• BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) is likely to report quarterly loss at $0.27 per share on revenue of $475 thousand. 
• Direct Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) is likely to report quarterly loss at $0.67 per share on revenue of $12.31 million. 
• Faraday Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) is expected to report earnings for its fourth quarter. 
• 374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) is likely to report quarterly loss at $0.02 per share on revenue of $100 thousand. 
• Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) is estimated to report earnings for its fourth quarter. 
• Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) is projected to report quarterly loss at $0.95 per share on revenue of $920 thousand. 
• Unusual Machines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#AMEX">UMAC</a>) is likely to report earnings for its fourth quarter. 
• BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) is expected to report earnings for its fourth quarter. 
• Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) is projected to report quarterly loss at $0.51 per share on revenue of $1.19 million. 
• VirTra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSI#NASDAQ">VTSI</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $8.09 million. 
• Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $5.37 million. 
• Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) is likely to report quarterly loss at $0.31 per share on revenue of $6.20 million. 
• Beachbody Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BODI#NYSE">BODI</a>) is likely to report quarterly loss at $1.52 per share on revenue of $81.71 million. 
• Stardust Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) is expected to report earnings for its fourth quarter. 
• Valhi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHI#NYSE">VHI</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $19.48 million. 
• Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $81.13 million. 
• Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) is projected to report quarterly loss at $0.05 per share on revenue of $12.80 million. 
• AAR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) is projected to report quarterly earnings at $0.96 per share on revenue of $679.95 million. 
• Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) is expected to report quarterly earnings at $1.28 per share on revenue of $383.94 million. 
• P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) is expected to report quarterly loss at $0.17 per share on revenue of $385.80 million. 
• Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) is likely to report quarterly loss at $0.34 per share on revenue of $375 thousand. 
• Argan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGX#NYSE">AGX</a>) is estimated to report quarterly earnings at $1.11 per share on revenue of $212.05 million. 
• HireQuest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQI#NASDAQ">HQI</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $9.30 million. 
• Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) is expected to report quarterly earnings at $5.65 per share on revenue of $3.52 billion. 
• Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) is likely to report quarterly loss at $0.11 per share on revenue of $294 thousand. 
• KULR Tech Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KULR#AMEX">KULR</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $2.87 million. 
• Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) is expected to report earnings for its fourth quarter. 
• Sky Harbour Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKYH#NYSE">SKYH</a>) is expected to report quarterly loss at $0.06 per share on revenue of $4.15 million. 
• Better Choice Co (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BTTR#AMEX">BTTR</a>) is likely to report earnings for its fourth quarter. 
• Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) is likely to report earnings for its fourth quarter. 
• Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $155.25 million. 
• Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) is likely to report quarterly loss at $0.14 per share on revenue of $68.43 million. 
• Spectral AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDAI#NASDAQ">MDAI</a>) is expected to report quarterly loss at $0.14 per share on revenue of $6.83 million. 
• Barfresh Food Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRFH#NASDAQ">BRFH</a>) is expected to report quarterly loss at $0.01 per share on revenue of $4.17 million. 
• Abacus Global Management (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) is expected to report quarterly earnings at $0.14 per share on revenue of $30.18 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAPG

ABOS

ADCT

BITF

BKTI

BKYI

The Beachbody Company, Inc. Class A Common Stock

BODI

BRFH

BRTX

BRZE

BTTR

BZAI

CLSD

CODX

DLPN

DPRO

DRCT

EDAP

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

FORA

FTLF

GEVO

ICCM

INMB

IPHA

IRIX

IZEA

JFIN

KULR

LTRN

LULU

LVLU

MDAI

NUTX

PDSB

PIII

PLSE

PSTV

RLMD

SACH

SCWO

SDST

SKYH

SPRO

SSKN

TLSI

TSAT

TSSI

UMAC

UONE

UONEK

VTSI

WKSP

Earnings Scheduled For March 27, 2025

Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) will release its quarterly earnings report on Thursday, 2025-03-27. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Geovax Labs to report an earnings per share (EPS) of $-0.95.
Investors in Geovax Labs are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Performance in Previous Earnings</h3>
Last quarter the company beat EPS by $0.57, which was followed by a 16.92% drop in the share price the next day.
Here's a look at Geovax Labs's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.48</td>
<td>-4.43</td>
<td>-3.15</td>
<td>-2.78</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.91</td>
<td>-1.99</td>
<td>-2.47</td>
<td>-3.94</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-17.0%</td>
<td>-1.0%</td>
<td>1.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1743012170_0.png" alt="eps graph" />
<h3>Tracking Geovax Labs's Stock Performance</h3>
Shares of Geovax Labs were trading at $1.37 as of March 25. Over the last 52-week period, shares are down 29.59%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/GOVX/earnings">To track all earnings releases for Geovax Labs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What's Next: Geovax Labs's Earnings Preview

<a href="https://geovax.com/investors/press-releases/geovax-labs-announces-4-5-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules" title="https://geovax.com/investors/press-releases/geovax-labs-announces-4-5-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules">https://geovax.com/investors/press-releases/geovax-labs-announces-4-5-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules</a>

Offerings

GeoVax Labs Announces $4.5M Registered Direct Offering  Of 3,435,115 Shares And Warrants At $1.31/Share And Accompanying Warrants

<a href="https://geovax.com/investors/press-releases/geovax-anticipates-significant-2025-progress-with-catalyst-rich-milestones-across-key-programs" title="https://geovax.com/investors/press-releases/geovax-anticipates-significant-2025-progress-with-catalyst-rich-milestones-across-key-programs">https://geovax.com/investors/press-releases/geovax-anticipates-significant-2025-progress-with-catalyst-rich-milestones-across-key-programs</a>

GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs

Harnessing AI to Revolutionize Vaccine and Therapy Development
ATLANTA, GA, February 3, 2025 — GeoVax Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>), a leader in vaccine and immunotherapy development, announced today its endorsement of President Donald J. Trump's Stargate Initiative, which aims to harness advanced technologies including Artificial Intelligence (AI) to strengthen U.S. healthcare, biosecurity, and global innovation leadership. This announcement aligns with GeoVax's commitment to leveraging AI across its vaccine and cancer immunotherapy programs to accelerate research, optimize operations, and deliver life-saving solutions.
Revolutionizing Healthcare with AI
GeoVax has embedded AI into its platforms for vaccine development and cancer immunotherapy, enabling groundbreaking advances:
<ul>
<li>Vaccine Development: AI drives target discovery and design for vaccines using the Modified Vaccinia Ankara (MVA) platform, including GEO-CM04S1, GeoVax's next-generation vaccine for COVID-19, and vaccines for Mpox and Smallpox. AI predicts pathogen mutations, ensuring long-lasting and variant-proof vaccines.</li>
<li>Cancer Immunotherapy: AI optimizes GeoVax's Gene-Directed Enzyme Prodrug Therapy (GDEPT) for solid tumors, including predictive modeling of tumor microenvironments, real-time adjustment of protocols to maximize therapeutic efficacy, and identifying synergistic combinations with immune checkpoint inhibitors.</li>
<li>Clinical Targeting: AI-powered analytics will refine patient stratification, ensuring that GeoVax's therapies reach underserved populations most in need, aligning with the initiative's national focus to maximize therapeutic efficacy.</li>
<li>Manufacturing and Operations: AI improves GeoVax's vaccine production scalability and supply chain management, ensuring timely delivery to strategic stockpiles.</li>
</ul>
Aligned with the Stargate Vision
President Trump's Stargate Initiative, supported by up to $500 billion in private-sector investment, represents a bold step forward in embracing transformative technologies. GeoVax proudly aligns with this vision, advancing U.S. healthcare innovation and pandemic preparedness.
David Dodd, GeoVax Chairman and CEO, stated: "President Trump's Stargate Initiative exemplifies leadership in harnessing AI to address critical healthcare challenges. GeoVax is honored to support this initiative, highlighting its application of AI to develop vaccines and therapies that save lives and enhance biosecurity. We are proud to contribute to a future where the United States leads the world in healthcare innovation."
Building on Operation Warp Speed's Legacy
GeoVax's efforts reflect the spirit of President Trump's Operation Warp Speed, which accelerated COVID-19 vaccine development and deployment. By integrating AI into its research and operational strategies, GeoVax aims to continue pushing the boundaries of what is possible in medical science.
A Commitment to Life-Saving Innovation
GeoVax remains steadfast in its mission to develop innovative vaccines and immunotherapies, leveraging the power of AI to meet the healthcare needs of today and prepare for the challenges of tomorrow. With AI now embedded in its processes, GeoVax anticipates shorter development timelines, increased efficiency in clinical trials, and enhanced capacity to deliver life-saving therapies globally. Collaborations with academic institutions, industry partners and federal agencies will further amplify the reach and impact of GeoVax's innovative programs under the Stargate framework. AI-enabled supply chain optimization will further ensure efficient vaccine distribution to high-priority populations and regions.

GeoVax Announces Strategic Integration Of AI In Support Of President Trump's Stargate Initiative; Harnessing AI To Revolutionize Vaccine And Therapy Development

Press Releases

GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference

GeoVax Receives Notice of Allowance For Cancer Vaccine Patent

Presenting on the Emerging Growth Conference 78 Day 1 on January 15 Register Now

Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now

Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now

Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now

Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream

Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

Comments

Geovax Labs

空売り

Geovax Labs (NASDAQ:GOVX) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル